ALK (R1275Q), GST-Tag Recombinant
Recombinant human ALK (R1275Q) (anaplastic lymphoma kinase), encompassing amino acids 1060-end with the R1275Q mutation. This construct contains an N-terminal GST-tag. The recombinant protein was affinity purified and is active.
90% (Purity calculation does not include co-purifying Glutathione-binding proteins.)
Aqueous buffer solution.
50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM Glutathione, 0.1 mM EDTA, 0.25 mM DTT, 0.1 mM PMSF, 25% glycerol
10 pmol/min/µg
ALK (anasplatic lymphoma kinase), also known as ALK tyrosine kinase receptor or CD246 (cluster of differentiation 246), is a receptor tyrosine kinase involved in signal transduction. In the presence of a ligand ALK dimerizes and a conformational change result in autoactivation of the kinase domain. Activated ALK will phosphorylate other ALK receptors and activate downstream signaling pathways. ALK is present in the nervous system during development, where it participates in retinal axon growth and targeting, synapse development, sleep, learning and long-term memory. Interestingly, dysfunction of ALK in one of three possible ways can lead to cancer: fusion with another gene, gene duplication or gene mutations. ALK, as its name indicates, has been linked to anaplastic large-cell lymphoma, but also non-small-cell lung cancer (NSCLC), neuroblastoma, breast cancer, renal carcinoma and others. Inhibitors of ALK show great therapeutical potential, two of them being already commercially available for the treatment of late-stage lung cancer and NSCLC. Further studies into ALK will deepen our understanding of its functions, find new inhibitors and new therapeutic avenues for patients with ALK-linked cancer.
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.